LuxCath, LLC is subsidiary developing a real-time lesion visualization monitoring tool for use during cardiac ablation procedures. The LuxCath technology is based on breakthroughs discovered by cardiologist Dr. Marco Mercader and colleagues at George Washington University.
Atrial Fibrillation (AF) is a commonly occurring cardiac arrhythmia or irregular heartbeat characterized by lower quality of life, higher morbidity and mortality; and is a common cause of stroke, affecting 2.5 million people in the U.S. alone. AF catheter ablation – an invasive procedure used to “disconnect” electrical pathway and restore normal heartbeat – is one of the fastest growing catheter-based cardiac procedures today. Radio Frequency Catheter Ablation (RFCA) is capable of blocking AF, however, to do so effectively and safely, a real-time damage monitoring tool is necessary. LuxCath is developing a catheter based real-time visualization monitoring tool for use during cardiac ablation procedures to ensure electrophysiologists are treating the right parts of the heart in atrial fibrillation patients effectively. This device should radically improve the speed of procedures and outcomes.
For more information please contact Omar Amirana, MD.